An Introduction to Leukaemia
Treating leukaemia holds numerous challenges, including the need for less toxic and more cost-effective treatments. Important additions to the landscape include targeted treatments such as FLT3 inhibitors, BCL-2 inhibitors and immune therapies such as monoclonal antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapies have been important additions to improve patient outcomes.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
The role of measurable residual disease in acute lymphoblastic leukaemia
Watch leading experts Aaron Logan, Joseph Khoury and Nicola Gökbuget discuss the importance of measurable residual disease reporting in acute lymphoblastic lymphoma, as well as best practice techniques, potential limitations, and future directions.
- Evaluate the evolving treatment landscape for acute lymphoblastic leukaemia
- Appraise the benefits and limitations of performing and reporting results for measurable residual disease
- Summarize how clinicians and pathologists can collaborate to use measurable residual disease testing to guide disease management
What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.
- Describe patients who may be eligible for treatment with CAR T-cell therapy
- Review the management of adverse events associated with CAR T-cell therapy
- Discuss how CAR T-cell therapy might impact the treatment pathway for new indications
Optimizing care with CAR T-cell therapy now and in the future for patients with B-cell malignancies
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.
- Recall the latest clinical trial and real-world data for CAR T-cell therapies in the management of B-cell malignancies
- Describe which patients are eligible for CAR T-cell therapy and discuss the optimal time for referral
- Discuss the safety profile of CAR T-cell therapy and the associated management strategies
- Describe data for new and emerging indications for CAR T-cell therapy
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Role of New Immunophenotypic Markers on Prognostic and Overall Survival of Acute Lymphoblastic Leukaemia – A Systematic Review and Meta-analysis
European Oncology & Haematology. 2019;15(2):113–20
Acute lymphoblastic leukaemia (ALL) is a group of malignant haematological disorders characterised by accumulation of lymphoid cell precursors that replace normal bone marrow elements and inhibit the production of functional blood cells.1 ALL occurs in both children and adults, and more than one-half (56%) of those diagnosed are <20 years old, with chemotherapy required as standard […]
Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia. Questions 1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05) 2. Following discontinuation of TKIs in patients with CML, when are […]
Naval Daver, ASH 2019: Venetoclax in Combination with Idasanutlin in Relapsed or Refractory AML
At the 61st ASH Annual Meeting & Exposition, Naval Daver, MD Anderson Cancer Center, discusses his presentation: Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Questions 1. What are the current therapeutic […]
Sabina Chiaretti, ASH 2019: Blinatumomab in Relapsed/Refractory Adult ALL
At the 61st ASH Annual Meeting & Exposition, Sabina Chiaretti, “Sapienza” University of Rome, discusses her presentation: Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. A Single Center Experience. Questions 1. What are the limitations of current therapeutic options for patients with relapsed/refractory acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!